Investigation of the roles of new antiepileptic drugs’ and serum BDNF levels in efficacy and safety monitoring and quality of life: a clinical research

Creative Commons License

Demir M., Akarsu E. O., Dede H. Ö., Bebek N., Yıldız S. Ö., Baykal B., ...More

Current Clinical Pharmacology, vol.15, no.1, pp.49-63, 2020 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 1
  • Publication Date: 2020
  • Doi Number: 10.2174/1574884714666190312145409
  • Journal Name: Current Clinical Pharmacology
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Agricultural & Environmental Science Database, Biotechnology Research Abstracts, EMBASE, MEDLINE
  • Page Numbers: pp.49-63
  • Keywords: Epilepsy, new antiepileptic drugs, TDM, safety, QOLIE-31, BDNF, efficacy, NEUROTROPHIC FACTOR, PHARMACOKINETIC INTERACTIONS, ILAE-COMMISSION, BRAIN, EPILEPSY, LAMOTRIGINE, EMPLOYMENT, MECHANISM, SEIZURES
  • Bezmialem Vakıf University Affiliated: Yes

Abstract

Objective: We aimed to determine the therapeutic drug monitoring (TDM) features and the relation to Brain-Derived Neurotrophic Factor (BDNF) of frequently used new antiepileptic drugs (NADs) including lamotrigine (LTG), oxcarbazepine (OXC), zonisamide (ZNS) and lacosamide (LCM). Moreover, we investigated their effect on the quality of life (QoL).